tiprankstipranks
Trending News
More News >
Surgical Science Sweden AB (SE:SUS)
:SUS
Sweden Market

Surgical Science Sweden AB (SUS) Price & Analysis

Compare
0 Followers

SUS Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

7.12%91.89%
Insiders
7.12%
Mutual Funds
― Other Institutional Investors
91.89% Public Companies and
Individual Investors

SUS FAQ

What was Surgical Science Sweden AB’s price range in the past 12 months?
Surgical Science Sweden AB lowest stock price was kr106.40 and its highest was kr192.40 in the past 12 months.
    What is Surgical Science Sweden AB’s market cap?
    Surgical Science Sweden AB’s market cap is kr7.75B.
      When is Surgical Science Sweden AB’s upcoming earnings report date?
      Surgical Science Sweden AB’s upcoming earnings report date is Aug 21, 2025 which is in 72 days.
        How were Surgical Science Sweden AB’s earnings last quarter?
        Surgical Science Sweden AB released its earnings results on May 14, 2025. The company reported kr0.7 earnings per share for the quarter, beating the consensus estimate of kr0.439 by kr0.261.
          Is Surgical Science Sweden AB overvalued?
          According to Wall Street analysts Surgical Science Sweden AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Surgical Science Sweden AB pay dividends?
            Surgical Science Sweden AB does not currently pay dividends.
            What is Surgical Science Sweden AB’s EPS estimate?
            Surgical Science Sweden AB’s EPS estimate is 0.73.
              How many shares outstanding does Surgical Science Sweden AB have?
              Surgical Science Sweden AB has 51,026,237 shares outstanding.
                What happened to Surgical Science Sweden AB’s price movement after its last earnings report?
                Surgical Science Sweden AB reported an EPS of kr0.7 in its last earnings report, beating expectations of kr0.439. Following the earnings report the stock price went up 5.385%.
                  Which hedge fund is a major shareholder of Surgical Science Sweden AB?
                  Currently, no hedge funds are holding shares in SE:SUS

                  SUS Stock 12 Month Forecast

                  Average Price Target

                  kr180.00
                  ▲(19.44%Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"119":"kr119","150":"kr150","181":"kr181","134.5":"kr134.5","165.5":"kr165.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr180.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[119,134.5,150,165.5,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Dec<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.7,140.95384615384614,144.2076923076923,147.46153846153845,150.7153846153846,153.96923076923076,157.22307692307692,160.47692307692307,163.73076923076923,166.98461538461538,170.23846153846154,173.4923076923077,176.74615384615385,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.7,140.95384615384614,144.2076923076923,147.46153846153845,150.7153846153846,153.96923076923076,157.22307692307692,160.47692307692307,163.73076923076923,166.98461538461538,170.23846153846154,173.4923076923077,176.74615384615385,{"y":180,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.7,140.95384615384614,144.2076923076923,147.46153846153845,150.7153846153846,153.96923076923076,157.22307692307692,160.47692307692307,163.73076923076923,166.98461538461538,170.23846153846154,173.4923076923077,176.74615384615385,{"y":180,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":155.2,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":151.7,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":157.1,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":144.6,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":125,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":127.9,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":120,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":122.9,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":127.9,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":149.5,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":155.9,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":155.9,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":137.7,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  CellaVision AB
                  Paxman AB
                  Senzime AB
                  C-Rad AB Class B
                  Vicore Pharma Holding AB
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis